Pharmaceutical, scientific & medical sales jobs
*Order all your Pharmaceutical,
Healthcare, Medical & Scientific books at Amazon
| |
|
|
Pharmaceutical, scientific & medical sales jobs
|
|
|
|
|
|
|||||||||
|
Categories |
Home - Pharmaceutical company directory, recruiters & resources UK Pharmaceutical DirectoryWelcome to Pharmaceutical.org.uk, where you will find useful weblinks and online resources pertaining to the UK Pharmaceutical Industry. In particular, this site features a Pharmaceutical Company directory, along with Pharmaceutical Sales, Pharmaceutical Jobs, Pharmaceutical Industry and Pharmaceutical News resources. UK Pharmaceutical IndustryPharmaceuticals are one of Britain’s leading manufacturing sectors, bringing in a trade surplus of £3.4 billion in 2004. The value of UK pharmaceutical exports in 2005 was £12,2 billion, more than £166,000 per employee. Yet we are low in the league of medicines expenditure: we spend much less than many of our European neighbours on the medicines we use. But our two largest pharmaceutical companies are among the most successful in the world. In a global industry such as pharmaceuticals, it is important to be in the Big League. An analysis of the world’s top 100 medicines reveals that, after the USA, Britain’s pharmaceutical companies’ market share is more than all its European competitors combined. Despite this success, British doctors are still reluctant to prescribe new medicines – clinicians in other countries are far more likely to prescribe medicines that have come on to the market in the past five years. [read more] Latest Pharmaceutical newsMyriad terminates Phase III Alzheimerâs disease therapy US-based Myriad Genetics has announced that it has discontinued development of tarenflurbil (Flurizan)... more Novexel discontinues MRSA agent Novexel has discontinued the development of its antibacterial agent, NXL-101 due to adverse events in a Phase I trial... more GlaxoSmithKline makes cancer cell genomic data available to all cancer researchers GlaxoSmithKline has released genomic profiling data for over 300 cancer cell lines via the US National Cancer Institute's cancer Bioinformatics Grid initiative... more Genzyme files plerixafor in the EU and the US Genzyme has filed for approval of its chemokine inhibitor plerixafor (Mobozil) in both the EU and US markets... more AstraZeneca submits sNDA for Seroquel XR for generalized anxiety disorder AstraZeneca's sustained release formulation of quetiapine fumarate (Seroquel XR) is now awaiting approval in the US for the treatment of generalised anxiety disorder (GAD)... more Myriad terminates Phase III Alzheimerâs disease therapy. Novexel discontinues MRSA agent. GlaxoSmithKline makes cancer cell genomic data available to all cancer researchers. Genzyme files plerixafor in the EU and the US. AstraZeneca submits sNDA for Seroquel XR for generalized anxiety disorder. World Asthma Day. Cimzia approved in the US for moderate-to-severe Crohn's disease. Perampanel development for Parkinson's disease terminated at Phase III. Paricalcitrol capsules lauched in the UK. Lilly enters its first Phase III trial for Alzheimer's disease. Acomplia set for launch in the UK market. EU approval for Boehringer Ingelheim's Pradaxa. European and US filings for eprodisate withdrawn. World Glaucoma Day. Glaxo terminates Phase III antimalarial. Phase III trial of sorafenib in lung cancer halted early. EU filing for Sanofi Pasteur's intradermal 'flu vaccine. US approval for a novel cholesterol management combination. Neose Technologies discontinues NE-180. Champix receives Japanese marketing authorization. Merck launches first-in-class HIV treatment in the UK. Second inhaled insulin product disappoints. Elan and Biogen Idec secure US approval for Crohn's disease therapeutic. Long-awaited submission of US NDA for prasugrel. Oncomed Pharmaceuticals adds anticancer antibody to GlaxoSmithKline's pipeline. First filing for J&J's novel anti-psoriasis antibody. Adolor and Pfizer join forces on novel pain compounds. World AIDS Day offers chance to reflect on recent therapeutic advances. Quark initiates Phase I trial of novel siRNA product for acute renal failure. Bad news for Vertex Pharmaceuticals' aurora kinase inhibitors. [read more] Latest updates: |
||||||||
|
|
|||||||||
|
|||||||||
|
| |
|
|
Copyright © Net Media Marketing. All rights reserved. |
|
 |
|
|
Other Pharmaceutical sites: JobsPharm.com | AllAboutMedicalSales.com | Pharmaceutical-Company.co.uk | Pharm.co.uk |
|
 |
|
